Damora Therapeutics, Inc. SEC filings DMRA
Damora Therapeutics, Inc. has 353 filings in SEC EDGAR's recent list, going back to Jan 16, 2020. Its latest annual report, Form ARS, was filed on May 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 20, 2026 (material agreement, change to shareholder rights, bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Jul 20, 2026 | Jul 16, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Apr 28, 2026 |
| 8-K |
Current report
Officer or director change
|
May 4, 2026 | Apr 28, 2026 |
| 8-K |
Current report
Auditor change
|
Apr 20, 2026 | Apr 17, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 23, 2026 | Mar 20, 2026 |
| 8-K |
Current report
Results of operations, Bylaw or fiscal year change, Regulation FD disclosure
|
Mar 10, 2026 | Mar 6, 2026 |
| 8-K |
Current report
Material agreement
|
Feb 11, 2026 | Feb 10, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Feb 10, 2026 | Feb 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Unregistered share sale, Officer or director change
|
Jan 6, 2026 | Dec 31, 2025 |
| 8-K/A |
Amended current report
Bylaw or fiscal year change
|
Dec 9, 2025 | Nov 10, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Nov 10, 2025 | Nov 10, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 20, 2025 | Jun 18, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2024 | Oct 15, 2024 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Oct 7, 2024 | Oct 7, 2024 |
| 8-K |
Current report
Other events
|
Sep 18, 2024 | Sep 16, 2024 |
| 8-K |
Current report
Other events
|
Sep 11, 2024 | Sep 10, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 5, 2024 | Aug 29, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2024 | Jun 20, 2024 |
| 8-K |
Current report
Other events
|
Mar 26, 2024 | Mar 22, 2024 |
| 8-K |
Current report
Other events
|
Dec 21, 2023 | Dec 21, 2023 |
| 8-K |
Current report
Other events
|
Oct 23, 2023 | Oct 23, 2023 |
| 8-K |
Current report
Listing notice
|
Oct 2, 2023 | Sep 27, 2023 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
Sep 26, 2023 | Sep 20, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 15, 2023 | Aug 15, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 15, 2023 | Jun 14, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 6, 2023 | Jan 6, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 31, 2022 | Oct 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2022 | Sep 29, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2022 | Jun 14, 2022 |
| 8-K |
Current report
Officer or director change
|
Feb 9, 2022 | Feb 3, 2022 |
| 8-K |
Current report
Other events
|
Jan 27, 2022 | Jan 27, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 5, 2022 | Jan 5, 2022 |
| 8-K |
Current report
Officer or director change
|
Jul 6, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Shareholder vote results
|
May 28, 2021 | May 26, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 15, 2021 | Mar 15, 2021 |
| 8-K |
Current report
Officer or director change
|
Jan 8, 2021 | Jan 8, 2021 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 5, 2021 | Jan 5, 2021 |
| 8-K |
Current report
Officer or director change
|
Nov 23, 2020 | Nov 19, 2020 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Nov 4, 2020 | Nov 2, 2020 |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DMRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1800315
- Former names
- Galecto, Inc. (until Mar 10, 2026); Galecto Inc. (until Oct 28, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.